Takeda’s Weber On Digitalizing Pharma In Ongoing Strategic Shift
China Now A Top Priority
Executive Summary
The entire pharmaceutical industry will transform itself with digital technology while still facing the challenge of financial balance as a part of the healthcare ecosystem, says Takeda's CEO, who shared his views on the firm’s and wider industry's shifting business and R&D strategies at the recent CPHI Japan meeting.
You may also be interested in...
Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
Global First Approval For Takeda's Dengue Vaccine, In Indonesia
Takeda’s dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to market a vaccine outside Japan and potentially paving the way to wider global use of vaccines for the mosquito-borne disease following setbacks for earlier contenders.
Takeda Sees Mainstays Tiding It Over Upcoming Expiries
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."